Rite Aid (RAD) surprised The Street today by reporting a profitable Q1 driven by strong pharmacy sales growth. Can drug stores such as Rite Aid and Walgreen’s (WAG) survive the threat from four-dollar-pill-pusher Wal-Mart (WMT).
Guy Adami tells the panel he still likes Rite Aid because the Brooks Eckerd deal will save them $150 million a year in perpetuity. And the deal gives Rite-Aid national exposure.
Jeff Macke also likes the stock.